Journal of Rheumatic Diseases

Table. 2.

Changes in HAQ-DI, EQ-5D-3L, SF-36 at week 12 and 24 after initiation of adalimumab

Instrument Value Change from baseline p-value

Mean±SD 95% CI
HAQ-DI
Baseline 1.29±0.71
Week 12 0.80±0.64 −0.46±0.60 −0.60, −0.33 <0.0001*
Week 24 0.63±0.56 −0.67±0.67 −0.83, −0.51 <0.0001*
Patients achieving a clinically meaningful improvement in HAQ-DI at week 12 52 (65.8)
Patients achieving a clinically meaningful improvement on HAQ-DI at 24 weeks 55 (77.5)
EQ-5D-3L
Baseline 0.59±0.22
Week 12 0.74±0.18 0.15±0.24 0.10, 0.20 <0.0001
Week 24 0.77±0.19 0.18±0.25 0.12, 0.24 <0.0001
SF-36 Physical component summary scores
Baseline 34.57±7.76
Week 12 41.26±7.56 6.56±6.98 7.67, 11.35 <0.0001
Week 24 43.91±7.07 9.51±7.77 7.67, 11.35 <0.0001
SF-36 Mental component summary scores
Baseline 35.88±11.51
Week 12 41.54±11.84 5.26±11.62 2.66, 7.87 0.0001
Week 24 43.00±11.62 6.63±12.31 3.71, 9.54 <0.0001

Values are presented as mean±standard deviation or number (%). HAQ-DI: Health Assessment Questionnaire Disability Index, EQ-5D-3L: EuroQol 5-dimension 3-Level, SF-36: Short Form 36-Item Health Survey, SD: standard deviation, CI: confidence interval. *p-value is from the test of mean change using ANOVA adjusting for baseline disease severity. Clinically meaningful improvement on HAQ-DI is defined as a −0.22 or greater point improvement. p-value is from the paired t-test testing the mean change.

J Rheum Dis 2021;28:68~75 https://doi.org/10.4078/jrd.2021.28.2.68
© J Rheum Dis